Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?

Future Oncol. 2024 Feb;20(4):163-166. doi: 10.2217/fon-2023-1019. Epub 2024 Feb 7.

Authors

Emilio Francesco Giunta¹, Lorenzo Gasperoni², Ugo De Giorgi¹

Affiliations

¹ Department of Medical Oncology, Meldola, Italy.
² Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.

PMID: 38323376
DOI: 10.2217/fon-2023-1019

No abstract available

Keywords: androgen deprivation therapy; castration; enzalutamide; patient-reported outcomes; prostate cancer; safety.

Publication types

Editorial

MeSH terms

Androgen Antagonists / therapeutic use
Benzamides
Humans
Leuprolide / therapeutic use
Male
Nitriles
Phenylthiohydantoin / therapeutic use
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

Leuprolide
enzalutamide
Phenylthiohydantoin
Benzamides
Nitriles
Androgen Antagonists